Format

Send to

Choose Destination
SLAS Discov. 2018 Sep;23(8):850-861. doi: 10.1177/2472555218773045. Epub 2018 May 9.

Application of Integrated Drug Screening/Kinome Analysis to Identify Inhibitors of Gemcitabine-Resistant Pancreatic Cancer Cell Growth.

Author information

1
1 Department of Pharmacology, University of North Carolina at Chapel Hill, NC, USA.
2
2 Structural Genomics Consortium, University of North Carolina at Chapel Hill, NC, USA.
3
3 Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC, USA.
4
4 Lineberger Cancer Center, University of North Carolina at Chapel Hill, NC, USA.
5
5 North Carolina Central University, Durham, NC, USA.

Abstract

Continuous exposure of a pancreatic cancer cell line MIA PaCa-2 (MiaS) to gemcitabine resulted in the formation of a gemcitabine-resistant subline (MiaR). In an effort to discover kinase inhibitors that inhibited MiaR growth, MiaR cells were exposed to kinase inhibitors (PKIS-1 library) in a 384-well screening format. Three compounds (UNC10112721A, UNC10112652A, and UNC10112793A) were identified that inhibited the growth of MiaR cells by more than 50% (at 50 nM). Two compounds (UNC10112721A and UNC10112652A) were classified as cyclin-dependent kinase (CDK) inhibitors, whereas UNC10112793A was reported to be a PLK inhibitor. Dose-response experiments supported the efficacy of these compounds to inhibit growth and increase apoptosis in 2D cultures of these cells. However, only UNC10112721A significantly inhibited the growth of 3D spheroids composed of MiaR cells and GFP-tagged cancer-associated fibroblasts. Multiplexed inhibitor bead (MIB)-mass spectrometry (MS) kinome competition experiments identified CDK9, CLK1-4, DYRK1A, and CSNK1 as major kinase targets for UNC10112721A in MiaR cells. Another CDK9 inhibitor (CDK-IN-2) replicated the growth inhibitory effects of UNC10112721A, whereas inhibitors against the CLK, DYRK, or CSNK1 kinases had no effect. In summary, these studies describe a coordinated approach to discover novel kinase inhibitors, evaluate their efficacy in 3D models, and define their specificity against the kinome.

KEYWORDS:

drug interactions; fluorescence methods; high-content screening; kinases; multiplex assays and technology

PMID:
29742358
PMCID:
PMC6102050
[Available on 2019-09-01]
DOI:
10.1177/2472555218773045

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center